Harprit Singh: Future – Ready Hospitals Will Have Apheresis Hubs, Not Just Dialysis Units
Harprit Singh, Associate Director at Transfusion Technologies, Therapies, Solutions and Consultant in Transfusion Medicine at Alchemist Hospital, shared a post on LinkedIn:
“Future – Ready Hospitals Will Have Apheresis Hubs – Not Just Dialysis Units
Most hospitals don’t have an apheresis problem.
They have a utilization problem.
In multiple institutions I’ve worked with, the pattern is consistent:
- Apheresis machines exist.
- Clinical expertise exists.
- But activation pathways don’t.
The result?
- Delayed therapeutic plasma exchange (TPE)
- Underutilized apheresis services
- Missed integration with solid organ and bone marrow transplant (BMT) and oncology
- Higher ICU burden and avoidable costs
This is where strategy changes everything.
Hospitals that build Clinical Apheresis Hubs – not fragmented services – unlock the following:
- Faster intervention in critical care
- Seamless transplant and cellular therapy workflows
- Reduced ICU dependency
High-value, predictable clinical revenue
Because an Apheresis Hub is not equipment.
It is a clinical plus operational plus financial system.
Protocols define speed
Ownership defines utilisation.
The question is no longer:
‘Do we have apheresis?’
It is:
‘Is it integrated into how we deliver care?’
For COs and administrators, this is where transfusion medicine becomes strategy – not support.
A practical starting point:
Map 3 things
Who triggers apheresis?
How fast can it be activated?
How often is iused?
An open question:
What is the single biggest barrier to apheresis utilisation in your institution today?”
Stay updated with Hemostasis Today.
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’